The association between the lupus anticoagulant and cerebral infarction in systemic lupus erythematosus.
The lupus anticoagulant (LAC) is associated with the occurrence of thromboembolic complications. Assuming that thrombosis may underlie manifestations of the central nervous system (CNS) in patients with systemic lupus erythematosus (SLE), we studied 20 patients with SLE and CNS manifestations for the presence of LAC. In 8 patients (40%) including 4 with overt cerebral infarction, LAC was demonstrated. The 4 patients with LAC and cerebral infarction all had thrombocytopenia, 2 had a history of peripheral thrombosis, and one recurrent abortion. In the 4 LAC-positive patients without overt cerebral infarction, thrombocytopenia was present in 3, a history of thrombosis in 2, and fetal wastage in one. We conclude that LAC identifies within the CNS-SLE group a subpopulation of patients in whom CNS manifestations are caused by cerebral infarction. This subpopulation is further characterized by increased prevalence of thrombocytopenia, peripheral thrombosis and fetal wastage. A possible pathogenetic role of LAC may be related to a hypercoagulable state occurring in this subgroup of SLE patients.
D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors* / Q000097:blood; D002493:Central Nervous System Diseases / Q000209:etiology; D002544:Cerebral Infarction / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D014057:Tomography, X-Ray Computed
D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor